Carter HB - Search Results

1

Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.

Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB, Marshall FF. Partin AW, et al. Among authors: carter hb. Urology. 1995 Feb;45(2):211-7. doi: 10.1016/0090-4295(95)80007-7. Urology. 1995. PMID: 7855968 Clinical Trial.

2

Expectant management of localized prostate cancer.

Khan MA, Partin AW, Carter HB. Khan MA, et al. Among authors: carter hb. Urology. 2003 Nov;62(5):793-9. doi: 10.1016/s0090-4295(03)00653-8. Urology. 2003. PMID: 14624896 Review. No abstract available.

3

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Partin AW, et al. Among authors: carter hb. J Urol. 1990 Apr;143(4):747-52. doi: 10.1016/s0022-5347(17)40079-6. J Urol. 1990. PMID: 1690309 Free article.

4

The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.

Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC. Carter HB, et al. J Urol. 1990 Nov;144(5):1167-70; discussion 1170-1. doi: 10.1016/s0022-5347(17)39683-0. J Urol. 1990. PMID: 1700143

5

Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge.

Carter HB, Partin AW, Coffey DS. Carter HB, et al. J Urol. 1989 Nov;142(5):1338-41. doi: 10.1016/s0022-5347(17)39093-6. J Urol. 1989. PMID: 2810530

6

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Partin AW, et al. Among authors: carter hb. Urology. 1994 May;43(5):649-59. doi: 10.1016/0090-4295(94)90180-5. Urology. 1994. PMID: 7513108

7

Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.

Cadeddu JA, Pearson JD, Lee BR, Landis P, Partin AW, Epstein JI, Carter HB. Cadeddu JA, et al. Among authors: carter hb. Urology. 1995 May;45(5):795-800. doi: 10.1016/s0090-4295(99)80086-7. Urology. 1995. PMID: 7538241

8

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. Partin AW, et al. Among authors: carter hb. J Urol. 1993 Jul;150(1):110-4. doi: 10.1016/s0022-5347(17)35410-1. J Urol. 1993. PMID: 7685418 Free article.

9

Relationship between changes in prostate-specific antigen and prognosis of prostate cancer.

Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB. Cadeddu JA, et al. Among authors: carter hb. Urology. 1993 Oct;42(4):383-9. doi: 10.1016/0090-4295(93)90362-e. Urology. 1993. PMID: 7692658 Free article.

10

Prostate-specific antigen in men born with bladder exstrophy.

Silver RI, Partin AW, Epstein JI, Chan DW, Carter HB, Jeffs RD, Gearhart JP. Silver RI, et al. Among authors: carter hb. Urology. 1997 Feb;49(2):253-6. doi: 10.1016/S0090-4295(96)00438-4. Urology. 1997. PMID: 9037290 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters